DENVER, CO — April 19, 2002 — Data presented at the American Academy of Neurology (AAN) annual meeting suggests that Zomig ® (zolmitriptan), a product of AstraZeneca, produces headache response as early as 30 minutes, increasing up to two hours, in women with migraine associated with menses.(1) The findings may be important for this subgroup of migraine sufferers that have been generally regarded as difficult to treat. Zomig is indicated for the acute treatment of migraine with or without aura in adults.
Migraine in women is often associated with onset of menses. Approximately 70 percent of all female migraineurs have attacks during menses, and between seven and 25 percent of these women experience migraine headaches almost exclusively during menses (menstrual migraine).(1)(2)
"Many women with migraine report that their headaches are more likely to occur with menstruation," observed Elizabeth Loder, M.D., Director of the Headache Management Program at the Spaulding Rehabilitation Hospital in Boston, and principal investigator of the study. "Like other migraine attacks, these can be debilitating, especially when associated with other symptoms such as nausea, cramping and backache. Effective treatment is very important for female migraineurs who experience menstrually associated migraine attacks."
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!